Verrica Pharmaceuticals stock price target raised to $20 by TD Cowen

Investing.com - TD Cowen raised its price target on Verrica Pharmaceuticals (NASDAQ:VRCA) to $20.00 from $5.00 on Wednesday, while maintaining a Buy rating on the stock. According to VRCA">InvestingPro data, the stock is currently trading below its Fair Value, despite showing a strong 11.5% return over the past week.

The significant price target increase comes as Verrica’s Ycanth product achieved $4.5 million in sales for the second quarter, reflecting 33% quarter-over-quarter growth in applicators dispensed.

TD Cowen noted that management is executing on its new strategy, which includes step-wise expansion and focus in key territories with high molluscum prevalence and strong insurance coverage.

The firm expressed optimism that Verrica’s new management team can continue to improve access to drive Ycanth adoption among patients.

The analyst maintained a Buy rating on Verrica Pharmaceuticals stock, citing continued focus on improving infrastructure to drive Ycanth demand.

In other recent news, Verrica Pharmaceuticals announced its Q2 2025 earnings, which exceeded analysts’ expectations. The company reported an earnings per share (EPS) of $0.02, while analysts had anticipated a loss of $0.09 per share. Additionally, Verrica Pharmaceuticals achieved revenue of $12.7 million, significantly surpassing the projected $4.11 million. These financial results mark a noteworthy performance for the company in the recent quarter. The positive earnings report has attracted attention from investors and analysts alike. While the stock experienced movement following the announcement, the focus remains on the company’s financial achievements. The recent developments highlight Verrica Pharmaceuticals’ ability to outperform market forecasts. Analyst firms are closely monitoring the company’s future performance based on these results.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.